Additionally, the progression free survival (PFS) analysis of the patients receiving chemotherapy in the cohort, showed AK2–LOXL3–DHODH axis should confer resistance for HCC patients to chemotherapy (Supplementary Fig. 7e). The gene discussed is AK2; the disease is hepatocellular carcinoma.